These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9371364)

  • 1. Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins.
    Deguchi T; Yasuda M; KawamuraT ; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Kawada Y
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2544-6. PubMed ID: 9371364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Kawamura T; Takahashi Y; Okezaki E; Nagata O; Kato H; Kawada Y
    J Antimicrob Chemother; 1997 Dec; 40(6):907-9. PubMed ID: 9462448
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
    Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
    Kitamura A; Hoshino K; Kimura Y; Hayakawa I; Sato K
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.
    Deguchi T; Fukuoka A; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Ban Y; Kawada Y
    Antimicrob Agents Chemother; 1997 Mar; 41(3):699-701. PubMed ID: 9056017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan.
    Tanaka M; Takahashi K; Saika T; Kobayashi I; Ueno T; Kumazawa J
    J Urol; 1998 Jun; 159(6):2215-9. PubMed ID: 9598572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene.
    Lascols C; Robert J; Cattoir V; Bébéar C; Cavallo JD; Podglajen I; Ploy MC; Bonnet R; Soussy CJ; Cambau E
    Int J Antimicrob Agents; 2007 Apr; 29(4):402-9. PubMed ID: 17254753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H; Kusano N
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Ezaki T; Saito I; Kawada Y
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1020-3. PubMed ID: 8849219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of mutations in gyrA, parC, and ompK35 in fluoroquinolone resistance in Klebsiella pneumoniae.
    Chen FJ; Lauderdale TL; Ho M; Lo HJ
    Microb Drug Resist; 2003; 9(3):265-71. PubMed ID: 12959405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.
    Piddock LJ; Hall MC; Walters RN
    J Antimicrob Chemother; 1991 Aug; 28(2):185-98. PubMed ID: 1663926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.